GLPBio

Cell Cycle/Checkpoint

Cell Cycle/Checkpoint

Cell Cycle

Cells undergo a complex cycle of growth and division that is referred to as the cell cycle. The cell cycle consists of four phases, G1 (GAP 1), S (synthesis), G2 (GAP 2) and M (mitosis). DNA replication occurs during S phase. When cells stop dividing temporarily or indefinitely, they enter a quiescent state called G0.

Research Areas

Products Related to Cell Cycle/Checkpoint(1447)

  • GC74159 structure
    GC74159MK-0731
    CAS: 845256-65-7
    Purity: >99.00%

    MK-0731 는 IC50이 2.2nM, pKa가 7.6인 선택적이고 비경쟁적이며 변형된 구동 단백질인 방추체 단백질(KSP) 억제제이다.

  • GC74279 structure
    GC74279Ganoderic acid T-Q
    CAS: 112430-66-7
    Purity: >99.00%

    Ganoderic acid T-Q (Ganodermic acid T-Q) (화합물 1)은 ganoderma lucidum에서 찾을 수있는 천연 제품입니다.

  • GC74280 structure
    GC74280Dihydrobaicalein
    CAS: 35683-17-1
    Purity: >99.00%

    Dihydrobaicalein 는 PLK1 억제제로서 IC50은 6.3 μM입니다.

  • GC74316 structure
    GC74316ATR kinase substrate peptide
    Purity: >99.00%

    ATR kinase substrate peptide (화합물 45)는 ATR (Ataxia Telangiectasia and Rad3 related) protein kinase (Ki=6 nM)의 강력하고 선택적인 억제제이다.

  • GC74326 structure
    GC74326MPSD TFA
    Purity: >98.00%

    MPSD TFA (MARCKS-ED TFA)는 MPSD의 TFA 소금 형태입니다.

  • GC74519 structure
    GC74519Cantuzumab ravtansine
    CAS: 868747-45-9
    Purity: >98.00%

    Cantuzumab ravtansine (IMGN242; huC242-DM4) 는 ADC의 일종이며 디유황 결합을 통해 DM4 (DM4) 에 연결되는 인적 유래화 단일 클론 항체 huC242입니다.

  • GC74533 structure
    GC74533Tusamitamab ravtansine
    CAS: 2254086-60-5
    Purity: >99.00%

    Tusamitamab ravtansine (SAR-408701)은 CEACAM5를 표현하는 종양세포를 대상으로 하는 표적 ADC로, 절단 가능한 조인트를 통해 강력한 세포독성제인 메덴소류 DM4와 함께 가격이 연결된 인원화 항CEACAM5 단클론 항체로 구성된다.

  • GC74600 structure
    GC74600Cofetuzumab pelidotin
    CAS: 1869937-48-3
    Purity: >99.00%

    Cofetuzumab pelidotin (PF-06647020) 는 PTK7을 표적으로 하는 ADC로서 인원화항 PTK7 단클론항체를 포함하며 발린산-과민산(vc) 기반의 절단가능한 이음매를 통해 auristatin 마이크로파이프억제제 유효하중 auristain-0101과 연결된다.

  • GC78758 structure
    GC78758Mal-Val-Lys-PAB-MMAE TFA
    Purity: >98.00%

    Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC.

  • GC78762 structure
    GC78762Trastuzumab-DM4
    Purity: >98%

    Trastuzumab -DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab with DM4 (sulfo-SPDB-DM4) via a cleavable linker.

  • GC78763 structure
    GC78763ADC Control Human IgG1-sulfo-SPDB-DM4
    Purity: >98.00%

    ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization.

  • GC78764 structure
    GC78764Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
    CAS: 3103526-19-5
    Purity: >97.50%

    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

  • GC78765 structure
    GC78765LP-6 TFA
    CAS: 1629741-09-8
    Purity: >98.00%

    LP-6 TFA is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs.

  • GC78766 structure
    GC78766N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)
    Purity: >98.00%

    N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.

  • GC78767 structure
    GC78767N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    Purity: >98.00%

    N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.

  • GC78791 structure
    GC78791AMG-172
    Purity: >98%

    AMG-172 is an antibody-drug conjugate ( ADC ) composed of a fully human IgG1 monoclonal anti- CD27L antibody conjugated to DM1 via the non-cleavable linker MCC.

  • GC78798 structure
    GC78798NN3201
    Purity: >99.00%

    NN3201 is a c-Kit -targeting antibody-drug conjugate ( ADC ) with high affinity ( K D = 0.19 pM).

  • GC78956 structure
    GC78956MYCMI-7 hydrobromide
    CAS: 102537-38-2
    Purity: >95.00%

    MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a K d of 4 μM for MYC and an IC 50 of 10 μM for topoisomerase IIα ( Topoisomerase II α ).

  • GC78959 structure
    GC78959c-Myc NLS TFA
    Purity: >98.00%

    c-Myc NLS TFA is a non-canonical nuclear localization signal (NLS) derived from the oncoprotein c-Myc, with the sequence PAAKRVKLD and containing 3 basic amino acids.

  • GC78960 structure
    GC78960DL78
    CAS: 132993-79-4
    Purity: >99.00%

    DL78 is an effective anti-mitotic agent.

  • GC78995 structure
    GC78995ZY39
    CAS: 2999673-51-5
    Purity: >99.50%

    ZY39 is a Sa ClpP agonist.

  • GC79000 structure
    GC79000Q901 TFA
    Purity: >98.50%

    Q901 (CDK7-IN-21) TFA is a selective and potent CDK7 inhibitor with an IC 50 of 10 nM.

  • GC79004 structure
    GC79004PMV6-PEG4-BI2536
    Purity: >98.00%

    PMV6-PEG4-BI2536 is an RIPTAC-like bifunctional molecule that promotes the formation of the p53 Y 220C -PLK1 ternary complex ( EC 50 = 1.4 μM).

  • GC79008 structure
    GC79008WY165
    Purity: >99.00%

    WY165 is a bifunctional molecule comprising TR79, an activator of the mitochondrial protease complex caseinolytic protease P ( ClpP ), linked to desthiobiotin.